Pilot study makes a strong early case for psilocybin as a treatment for anorexia nervosa, with notable symptom improvement and acceptable safety signals

Psilocybin is emerging as a potential treatment for anorexia nervosa after a pilot study reported meaningful symptom improvement alongside acceptable safety and tolerability. The findings add to growing interest in psychedelic-assisted care for hard-to-treat eating disorders, where current options often have limited effectiveness. Participants in the small early-stage study showed reductions in eating-disorder psychopathology, and some also experienced gains in mood, flexibility, or quality of life. The study design and sample size limit strong conclusions, but the signal is notable because anorexia has high morbidity, complex psychiatric overlap, and few reliably effective interventions. Psilocybin's relevance here centers on its possible ability to disrupt rigid thought patterns, reduce fear-based avoidance, and support psychological change when paired with therapeutic support. Larger controlled trials are still needed to determine durability, comparative benefit, and which patients may respond best.